SUPERSEDED Local Coverage Determination (LCD)

Endoscopy by Capsule

L34081

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
CGS Administrators, LLC	MAC - Part A	15101 - MAC A	J - 15	Kentucky
CGS Administrators, LLC	MAC - Part B	15102 - MAC B	J - 15	Kentucky
CGS Administrators, LLC	MAC - Part A	15201 - MAC A	J - 15	Ohio
CGS Administrators, LLC	MAC - Part B	15202 - MAC B	J - 15	Ohio

LCD Information

Document Information

LCD ID
L34081

LCD Title
Endoscopy by Capsule

Proposed LCD in Comment Period
N/A

Source Proposed LCD
N/A

Original Effective Date
For services performed on or after 10/01/2015

Revision Effective Date
For services performed on or after 03/02/2023

Revision Ending Date
03/06/2024

Retirement Date
N/A

Notice Period Start Date
N/A

Notice Period End Date
N/A

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Issue

Issue Description

This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations and/or Medical Necessity.

CMS National Coverage Policy

Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See §1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act (SSA):

Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

Code of Federal Regulations:

42 CFR 410.32 indicates that diagnostic tests may only be ordered by a treating physician (or other treating practitioner acting within the scope of their license and Medicare requirements) who furnishes a consultation or treats a beneficiary for a specific medical problem and who uses the results in the management of the beneficiary's specific medical problem. Tests not ordered by the physician (or other qualified non-physician provider) who is treating the beneficiary are not reasonable and necessary (see Sec. 411.15(k)(1) of this chapter

CMS Publications:

CMS Publication 100-04, Medicare Claims Processing Manual, Chapter 23:

10.1 - 10.1.7 ICD-9-CM Coding for Diagnostic Tests.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Abstract:

Endooscopy by capsule is carried out by a wireless video capsule that is swallowed and ultimately passed from the rectum. Two capsules are available, one designed for the small bowel and one for the esophagus. This LCD outlines coverage guidelines for conditions involving the small bowel where small bowel capsule use may be helpful for diagnosis. This LCD also defines coverage for the esophageal capsule in a subgroup of patients with hepatic cirrhosis to identify medium-large esophageal varices.

Indications:

The indications below were derived in part from The American Society for Gastrointestinal Endoscopy (ASGE) Technology Status Evaluation Report:Wireless Capsule Endoscopy

Endoscopy by Capsule of the Esophagus
The esophageal capsule is a wireless diagnostic video capsule specifically designed for visualization of the esophagus. The device acquires video images via camera ports at both ends as it travels through the esophagus. No sedation is required for the procedure.

There is a high mortality associated with bleeding from esophageal varices. Treatment with beta blockers or variceal ligation is generally accepted to reduce the incidence of first bleeding in patients with medium to large varices. Consequently triage of cirrhotics into those with medium-large varices or none-small varices is reasonable to determine who should be treated. Capsule endoscopy of the esophagus is an alternative to conventional endoscopy in cirrhotic patients who are anticipated to tolerate adequate doses of beta-blockers (see documentation requirements). Cirrhotic patients unlikely to tolerate beta-blockers should be examined with conventional endoscopy so that variceal ligation may be performed if indicated. Since variceal size estimates should be comparable to estimates made by conventional endoscopy the capsule endoscopist should use a previously validated algorithm to estimate variceal size. The recommended algorithm to estimate variceal size by capsule endoscopy was developed from the initial pilot data (Eisen et al. Endoscopy 2006) and subsequently used and validated (compared to conventional endoscopy) in a multi-center international trial (De Franchis et al. presented at Digestive Disease Week 2007). In this algorithm a varix is considered small if the diameter is greater than zero and less than 1/4 of the video circumference for the frame that shows its largest diameter. It is considered medium/large if this measurement is greater than or equal to 1/4 of the circumference.

Evaluation for esophageal varices is reasonable in patients with cirrhosis and portal hypertension and no prior variceal bleeding. Cirrhosis and portal hypertension is defined for this policy as a Child's class B or C stage or a class A with a low platelet count (<140,000), an enlarged portal vein diameter (> 13 mm), or evidence of collateral circulation on ultrasound (see Grace ND et al).

For those patients diagnosed with medium to large varices subsequent capsule endoscopy would not be reasonable. However, coverage for conventional flexible endoscopy would be available when reasonable and necessary.

The American Society for Gastrointestinal Endoscopy suggests repeat evaluation in 3-year intervals for those without varices and in 1 to 2 years for those with small varices.

Endoscopy by Capsule of the Small Intestine
It may be an adjunctive tool used in the detection of abnormalities of the small bowel, which is not accessible to standard upper endoscopy and colonoscopy. A small capsule is swallowed and moves through the GI tract propelled by peristalsis, transmitting video pictures. The video images are transmitted to sensors taped to the body and stored on a portable recorder. The strength of the signal is used to calculate the position of the capsule as it passes through the GI tract. Video images are stored on a portable recorder and later downloaded to a computer, from which they may be viewed. The capsule passes naturally from the body with the stool, and since it is disposable, it is not recovered.

Gastrointestinal Bleeding
The test is indicated for the diagnosis of occult gastrointestinal bleeding, the site of which has not been identified previously by any of the following: upper gastrointestinal endoscopy, colonoscopy, push enteroscopy, nuclear imaging, or radiological procedures. The test is especially helpful in the diagnosis of angiodysplasias of the gastrointestinal tract.

Endoscopy by capsule is limited to those patients who have generally undergone both upper GI endoscopy and colonoscopy, and when these tests have failed to reveal a source of bleeding. In rare situations where hemotemesis occurs repeatedly and upper GI endoscopy is repeatedly negative capsule endoscopy may be indicated.

Small Bowel Neoplasm
The test is indicated for the detection of neoplasms of the small bowel, when the diagnosis has not been previously confirmed by other studies (e.g., upper gastrointestinal endoscopy, colonoscopy, push enteroscopy, nuclear imaging, or radiological procedures). The patient must be symptomatic for a neoplasm (e.g., GI bleeding) or have a documented polyposis syndrome that is associated with small bowel neoplasia or there is other history suggesting the presence of small bowel neoplasia and other diagnostic testing to assess these symptoms (i.e., upper GI endoscopy and/or colonoscopy) must have been performed. Endoscopy by capsule may be indicated for the detection of small bowel neoplasm in those patients with documented intussusception of the small bowel, without established etiology. In such instances the requirement for prior examination by upper and lower endoscopies may be waived.

Crohn's Disease
Endoscopy by capsule is indicated for the diagnosis of Crohn's disease when the condition has not been previously confirmed or gastrointestinal capsule imaging is indicated when a diagnosis of colitis of an indeterminate type affecting the colon is known, and a more specific diagnosis is sought by evaluating for possible small bowel involvement. Endoscopy by capsule is reasonable in those patients in whom there is strong clinical suspicion of Crohn's disease (with abdominal pain, weight loss, diarrhea, anorexia, bleeding and biochemical indicators of inflammation) and in whom, in the physician's judgment, there is no intestinal stricture. In these patients with a strong clinical suspicion of Crohn's disease, negative colonoscopy is a prerequisite to the performance of the capsule endoscopy.

Other Conditions
Evaluation of malabsorption syndrome, chronic diarrhea, or protein-losing enteropathy of obscure origin is reasonable when it is suspected to originate in the small intestinal mucosa. Appropriate prior negative or non-diagnostic evaluations of the esophagus, stomach, duodenum/small intestine, and colon by flexible endoscopy, and complementary radiologic procedures and/or microbiologic studies must be documented.

Evaluation Prior to Surgery
Evaluation of extent of small bowel involvement with arteriovenous malformations or lymphangiectasia for patients who are contemplated for surgical resection of the small bowel to control recurrent bleeding or protein loss is reasonable.

Limitations:

Endoscopy by Capsule of the Esophagus

Medicare contractor local coverage determinations (LCDs) generally cover esophagoscopy in patients with Gastroesophageal Reflux Disease (GERD) symptoms that persist despite appropriate therapy. The American College of Gastroenterology (ACGE) states in regard to empirical therapy for GERD: "Further diagnostic testing should be considered if the patient does not respond to therapy, when there are alarm symptoms suggesting complicated disease (dysphagia, odynophagia, bleeding, weight loss, or anemia) and when patients have a sufficient duration of symptoms to put them at risk for Barrett's esophagus."

The American Society for Gastrointestinal Endoscopy states "When there are clinical clues that suggest that reflux may be severe or that other diseases may be present, endoscopy is the diagnostic procedure of choice."

The reported frequency of Barrett's esophagus in those with reflux symptoms ranges from 5% to 15%, and these patients without significant inflammatory changes undergo biopsy at the time of endoscopy.

Indications for endoscopy in GERD assume that endoscopy has the potential to obtain tissue samples and to examine the stomach and duodenum. Since the capsule does not have these capabilities, the above recommendations cannot be carried over to the capsule.

Until a clear description of the population who would benefit from endoscopy by capsule (patients who do not need evaluation of the stomach and duodenum and who do not need initial biopsies) becomes available, endoscopy by capsule is not covered for GERD evaluation.

Patency Capsule Testing
Patency Capsule Testing will also not be covered. Sufficient peer-reviewed literature supporting its use is not currently available. On occasion Patency Capsule has been reported to cause obstruction requiring urgent intervention.

The ASGE Technology Status Evaluation Report Wireless Capsule Endoscopy lists, "Patients with known or suspected gastrointestinal (GI) obstruction, strictures, or fistulas based on the clinical picture or preprocedure testing" under contraindications for the small bowel capsule.

Endoscopy by Capsule of the Small Intestine
ICD-10-CM codes K58.0 or K58.9 and R10.11-R10.13, R10.2, R10.31-R10.33, or R10.84 for irritable bowel syndrome and abdominal pain have been placed on the list of covered diagnoses for use when a capsule endoscopy exam is normal in the face of compelling symptoms. When representing chronic stable symptoms, these conditions rarely represent reasonable indications for endoscopy by capsule. When these diagnostic codes are used, the codes must be applicable and the rationale for capsule endoscopy must be carefully documented in the medical record.

The ingestion of the capsule is part of the test and an evaluation & management (E&M) service may not be billed for this purpose.

Endoscopy by capsule of the small intestine is not covered in the following situations:

Colorectal cancer screening
When carried out by FDA non-approved devices
Confirmation of lesions or pathology normally within the reach of upper or lower endoscopy (lesions proximal to the ligament of Treitz or distal to the ileum) or for the confirmation of lesions or pathology discovered by prior endoscopy (including push enteroscopy), colonoscopy, or radiology
When performed by physicians not trained in endoscopy or for independent diagnostic testing facilities, which are not under the general supervision of a physician trained in endoscopy procedures.

Endoscopy by capsule performed to diagnose obscure gastrointestinal bleeding, is only covered if it is documented that the beneficiary had continuing GI blood loss or anemia secondary to bleeding or iron deficiency anemia.

Endoscopy by capsule is not generally reimbursable when used for management of patients with a confirmed diagnosis of Crohn's disease. Onset of new symptoms suggestive of Crohn's disease at an undiagnosed small bowel region may make endoscopy by capsule reasonable.

Endoscopy by capsule for the detection of small bowel malignancies, in the absence of obscure gastrointestinal bleeding, or symptoms suggesting Crohn's disease, or the presence of a polyposis syndrome associated with small bowel neoplasia or other history suggesting the presence of small bowel neoplasia is not covered.

Endoscopy by capsule of the esophagus is not covered in patients with a current history of dysphagia suggestive of esophageal stricture.

Other Comments:

For claims submitted to the Part A MAC: this coverage determination also applies within states outside the primary geographic jurisdiction with facilities that have nominated CGS Administrators, LLC to process their claims.

Bill type codes only apply to providers who bill these services to the Part A MAC. Bill type codes do not apply to physicians, other professionals and suppliers who bill these services to the carrier or Part B MAC.

For dates of service prior to April 1, 2010, FQHC services should be reported with bill type 73X. For dates of service on or after April 1, 2010, bill type 77X should be used to report FQHC services.

Limitation of liability and refund requirements apply when denials are likely, whether based on medical necessity or other coverage reasons. The provider/supplier must notify the beneficiary in writing, prior to rendering the service, if the provider/supplier is aware that the test, item or procedure may not be covered by Medicare. The limitation of liability and refund requirements do not apply when the test, item or procedure is statutorily excluded, has no Medicare benefit category or is rendered for screening purposes.

Summary of Evidence

N/A

Analysis of Evidence (Rationale for Determination)

N/A

Proposed Process Information

Synopsis of Changes

Changes	Fields Changed
	N/A

Associated Information

Sources of Information

Bibliography

Open Meetings

Contractor Advisory Committee (CAC) Meetings

MAC Meeting Information URLs

Proposed LCD Posting Date

Comment Period Start Date

Comment Period End Date

Reason for Proposed LCD

Requestor Name	Requestor Letter
	View Letter

Requestor Information

Contact for Comments on Proposed LCD

Coding Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

ICD-10-CM Codes that Support Medical Necessity

ICD-10-CM Codes that DO NOT Support Medical Necessity

Additional ICD-10 Information

General Information

Associated Information

The patient's medical record must contain documentation that fully supports the medical necessity for services included within this LCD. (See "Indications and Limitations of Coverage.") This documentation includes, but is not limited to, relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures.

Medical record documentation must be available to Medicare upon request. Photographic copies of the video images, with the beneficiary's name and the date of service included in the picture, must be available for review.

Additional documentation is required according to the specific indication for performing endoscopy by capsule:

If the beneficiary has GI blood loss or iron deficiency anemia or anemia secondary to the bleeding, the medical record must document that the prior upper GI endoscopy or colonoscopy failed to adequately reveal the source of bleeding.
If the provisional diagnosis is occult gastrointestinal bleeding without iron deficiency anemia, the medical record must document the presence of occult blood in fecal samples.
If the provisional diagnosis is Crohn's disease, the medical record must document the signs, symptoms, and previous diagnostic work supporting this diagnosis.
If the provisional diagnosis is Crohn's the medical record must document that, in the physicians's judgment, the patient does not have an intestinal stricture.
If small bowel involvement is suspected in a patient with known Crohn's disease or other colitis, the medical record must document the signs, symptoms, and previous diagnostic work supporting this hypothesis.
The medical record must document the need for capsule endoscopy and contain reports or reference to the previous appropriate negative endoscopies performed prior to endoscopy by capsule.

For capsule endoscopy of the esophagus the record must document that the patient does not have a contraindication for nonselective beta-blocker use. The presence of this documentation must be indicated with claim submission by use of the KX modifier. Examples of likely contraindications would be bronchial asthma, sinus bradycardia and greater than first degree heart block and overt congestive heart failure.

Not applicable

Endoscopy by capsule of the small intestine will be covered once per episode of illness. Services exceeding this parameter will be considered not medically necessary.

Claims for additional tests will be denied as not medically necessary in the absence of supportive documentation.

Sources of Information

This bibliography presents those sources that were obtained during the development of this policy. CGS Administrators, LLC is not responsible for the continuing viability of Web site addresses listed below.

Appleyard M, Fireman Z, Glukhovsky A, et al. A randomized trial comparing wireless capsule endoscopy with push enteroscopy for the detection of small-bowel lesions. Gastroenterology. 2000;119:1431-1438.

Appleyard M, Glukhovsky A, Swain P. Wireless-capsule diagnostic endoscopy for recurrent small-bowel bleeding. N Engl J Med. 2001;344:232-233.

Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol. 2005;19:15-35.

Barkay O, Moshkowitz M, Fireman Z, et al. Initial experience of videocapsule endoscopy for diagnosing small-bowel tumors in patients with GI polyposis syndromes. Gastrointest Endosc. 2005;62:448-452.

Boivin ML, Lochs H, Voderholzer WA. Does passage of a patency capsule indicate small-bowel patency? A prospective clinical trial? Endoscopy. 2005;37:808-815.

Catanzaro A, Faulx A, Isenberg GA, et al. Prospective evaluation of 4-mm diameter endoscopes for esophagoscopy in sedated and unsedated patients. Gastrointest Endosc. 2003;57:300-304.

D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475-505.

De Franchis R, Eisen GM, Eliakim R, et al. Esophageal capsule endoscopy (Pillcam ESO) is comparable to traditional endoscopy for detection of esophageal varices-An international Multi-center trial. 2007. Ref Type: (Unpublished Work). Presented at 2007 Digestive Week Scientific Meeting, Washington, D.C.

Dellon ES, Shaheen NJ. Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival? J Clin Oncol. 2005;23:4478-4482.

Desmond AN, O'Regan K, Curran C, et al. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut. 2008;57(11):1489-1490.

DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190-200.

Eisen GM, Baron TH, Dominitz JA, et al. Complications of upper GI endoscopy. Gastrointest Endosc. 2002;55:784-793.

Eisen GM, Eliakim R, Zaman A, et al. The accuracy of PillCam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: a prospective three-center pilot study. Endoscopy. 2006;38:31-35.

Eliakim R, Sharma VK, Yassin K, et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol. 2005;39:572-578.

Gay G, Delvaux M, Laurent V, et al. Temporary intestinal occlusion induced by a "patency capsule" in a patient with Crohn's disease. Endoscopy. 2005;37:174-177.

Goldfarb NI, Pizzi LT, Fuhr JP, et al. Diagnosing crohn's disease: an economic analysis comparing wireless capsule endoscopy with traditional diagnostic procedures. Disease Management. 7(4):292-304.

Grace ND, Groszmann RJ, Garcia-Tsao G, et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology. 1998;28:868-880.

Hahne M, Adamek HE, Schilling D, Riemann JF. Wireless capsule endoscopy in a patient with obscure occult bleeding. Endoscopy. 2002;34:588-590.

Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199-211.

Herrerias JM, Leighton JA, Costamanga, G, et al. Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointestinal Endoscopy. 2008:1-8.

Idezuki Y. General rules for recording endoscopic findings of esophagogastric varices (1991). Japanese Society for Portal Hypertension. World J Surg. 1995;19:420-422.

Kamath PS. Esophageal variceal bleeding: primary prophylaxis. Clin Gastroenterol Hepatol. 2005;3:90-93.

Leighton JA, Goldstein J, Hirota W, et al. Obscure gastrointestinal bleeding. Gastrointest Endosc. 2003;58:650-655.

Leighton JA, Shen B, Baron TH, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006;63:558-565.

Lewis, BS. Expanding role of capsule endoscopy in inflammatory bowel disease. World J Gastroenterol. 2008;14(26):4137-4141.

Lewis BS, Eisen GM, Friedman S. A pooled analysis to evaluate results of capsule endoscopy trials. Endoscopy. 2005;37(10):960-965.

Maieron A, Hubner D, Blaha B, et al. Multicenter retrospective evaluation of capsule endoscopy in clinical routine. Endoscopy. 2004;36:864-868.

Marmo R, Rotondano G, Piscopo R, et al. Capsule endoscopy versus enteroclysis in the detection of small-bowel involvement in Crohn's disease: a prospective trial. Clin Gastroenterol Hepatol. 2005;3:772-776.

Marmo R, Rotondano G, Piscopo R, Bianco MA, Cipolletta L. Meta-analysis: capsule endoscopy vs. conventional modalities in diagnosis of small bowel diseases. Ailment Pharmcol Ther. 2005;22:595-604.

Mata A, Bordas JM, Feu F, et al. Wireless capsule endoscopy in patients with obscure gastrointestinal bleeding: a comparative study with push enteroscopy. Aliment Pharmacol Ther. 2004;20:189-194.

Merkel C, Zoli M, Siringo S, et al. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Am J Gastroenterol. 2000;95:2915-2920.

Mishkin DS, Chuttani R, Croffie J, et al. ASGE Technology Status Evaluation Report: wireless capsule endoscopy. Gastrointest Endosc. 2006;63:539-545.

Olliver JR, Hardie LJ, Gong Y, et al. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2005;14:620-625.

Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. N Engl J Med. 1988;319:983-989.

Qureshi W, Adler DG, Davila R, et al. ASGE Guideline: the role of endoscopy in the management of variceal hemorrhage, updated July 2005. Gastrointest Endosc. 2005;62:651-655.

Reliability of endoscopy in the assessment of variceal features. The Italian Liver Cirrhosis Project. J Hepatol. 1987;4:93-98.

Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670-1677.

Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002;97:1888-1895.

Sharma P, Sidorenko EI. Are screening and surveillance for Barrett's oesophagus really worthwhile? Gut. 2005;54 Suppl 1:i27-i32.

Tatar EL, Shen EH, Palance AL, Sun JH, Pitchumoni CS. Clinical utility of wireless capsule endoscopy: experience with 200 cases. J Clin Gastroenterol. 2006;40:140-144.

The role of endoscopy in the management of GERD: guidelines for clinical application. From the ASGE. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc. 1999;49:834-835.

Triester SL, Leighton JA, Leontiadis GI, et al. A meto-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel crohn's disease. Am J Gastoenterol. 2006;101:954-964.

Veldhuyzen van Zanten SJ, Bradette M, Chiba N, et al. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can J Gastroenterol. 2005;19:285-303.

Westhoff B, Brotze S, Weston A, et al. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc. 2005;61:226-231.

Wildi SM, Glenn TF, Woolson RF, Wang W, Hawes RH, Wallace MB. Is esophagoscopy alone sufficient for patients with reflux symptoms? Gastrointest Endosc. 2004;59:349-354.

Winters C, Jr., Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118-124.

Zoli M, Merkel C, Magalotti D, Marchesini G, Gatta A, Pisi E. Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology. 1996;24:1047-1052.

Other Medicare contractor policies consulted in development of the draft:

AdminaStar Federal fiscal intermediary LCD (Illinois [L13708], Indiana [L13707], Kentucky [L13709], Ohio [L13710])
Associated Hospital Services fiscal intermediary LCDs (Maine [L23048], Massachusetts [L23050])
Anthem Health Plans of New Hampshire fiscal intermediary LCD [L22853]
Empire Medicare Services carrier LCD (New Jersey [L4244], New York [L3589])

Bibliography

N/A

Revision History Information

Revision History Date	Revision History Number	Revision History Explanation	Reasons for Change
03/02/2023	R17	R16 Revision Effective: 03/02/2023 Revision Explanation: Annual Review, no changes were made. 02/15/2023: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Other (Annual Review)
03/03/2022	R16	R15 Revision Effective: 03/03/2022 Revision Explanation: Annual Review, no changes were made 02/23/2022: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Other (Annual Review)
03/04/2021	R15	R14 Revision Effective: 03/05/2021 Revision Explanation: Annual Review, no changes were made 02/24/2021: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Other (Annual Review)
09/19/2019	R14	R13 Revision Effective: N/A Revision Explanation: Annual Review, no changes made 02/28/2020:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Other (Annual Review)
09/19/2019	R13	R12 Revision Effective: 09/19/2019 Revision Explanation: Converted policy into new policy template that no longer includes coding section based on CR 10901. For Approval, no changes. 09/13/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Revisions Due To Code Removal
09/19/2019	R12	R11 Revision Effective: 09/19/2019 Revision Explanation: Converted policy into new policy template that no longer includes coding section based on CR 10901. 09/12/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Revisions Due To Code Removal
10/01/2017	R11	R10 Revision Effective: N/A Revision Explanation: Annual review no changes made. 02/20/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Other (Annual Review)
10/01/2017	R10	R9 Revision Effective: N/A Revision Explanation: Annual review no changes made. 02/26/2018:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Other (Annual Review)
10/01/2017	R9	R8 Revision Effective: 10/01/2017 Revision Explanation: During ICD-10 annual review K56.60 was deleted from group1 and replaced with K56.600, K56.601, and K56.609. At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	Revisions Due To ICD-10-CM Code Changes
10/01/2016	R8	R7 Revision Effective: N/A Revision Explanation: added date for annual review completed.	Typographical Error
10/01/2016	R7	R6 Revision Effective: N/A Revision Explanation: Annual review no changes made.	Other (Annual Review)
10/01/2016	R6	R5 Revision Effective: 10/01/2016 Revision Explanation: Corrected revision date to 10/01/2016 instead of 10/01/2015.	Typographical Error
10/01/2015	R5	R4 Revision Effective: 10/01/2016 Revision Explanation: Z98.890, K52.2, and K90.4 were deleted during annual ICD-10 update and replaced with the following effective 10/01/2016: K52.21 K52.22, K52.29, K52.3(new 2017), K90.41, K90.49, Z98.890, Z98.891	Revisions Due To ICD-10-CM Code Changes
10/01/2015	R4	R3 Revision Effective: N/A Revision Explanation: Annual review no changes made.	Other (Annual Review)
10/01/2015	R3	Revision R2 Revision Effective: 10/01/2015 Revision Explanation: Removed ICD-10 codes Z97.8, Z98.3, and Z98.62 from group one after review and found these codes do not fit this policy.	Typographical Error
10/01/2015	R2	R2 Revision Effective: 10/01/2015 Revision Explanation: Removed ICD-10 codes Z97.8, Z98.3, and Z98.62 after review and found these codes do not fit this policy.	Reconsideration Request
10/01/2015	R1	R1 Reveiosn Effective: 10/01/2015 Revision Explanation: Accepted revenue code description changes.	Other (revenue code)

Associated Documents

Attachments
N/A

Related Local Coverage Documents
Articles
A56461 - Billing and Coding: Endoscopy by Capsule

Updated On	Effective Dates	Status
02/28/2024	03/07/2024 - N/A	Currently in Effect	View
02/23/2023	03/02/2023 - 03/06/2024	Superseded	You are here
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A

Read the LCD Disclaimer

License Agreements
American Medical Association Current Procedural Terminology
American Dental Association Current Dental Terminology
American Hospital Association NUBC UB-04

Please review the licensing information below and indicate your agreement and acceptance.

License for Use of Current Procedural Terminology (CPT)

End User Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees, and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza, 330 Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, AMA Plaza, 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of FAR 52.227-14 (December 2007) and/or subject to the restricted rights provisions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CPT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material contained on this page. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

License For Use of Current Dental Terminology (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood, and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org/ http://www.ADA.org/.

Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use.

Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES

CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values, or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.

CMS DISCLAIMER

The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead, you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/ http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Endoscopy by Capsule

Document Note

Note History

Contractor Information

LCD Information

Document Information

Issue

CMS National Coverage Policy

Coverage Guidance

Proposed Process Information

Coding Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

CPT/HCPCS Codes

Please accept the License to see the codes.

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Additional ICD-10 Information

General Information

Revision History Information

Associated Documents

Keywords

Page Help for LCD - Endoscopy by Capsule (L34081)

Introduction

More information

Tracking Sheet

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS